Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q3 2020 · 10-Q
Revenue$647.26M$647.26M+15.5% vs Q3 2019 Net Income$1.31B$1.31BN/M vs Q3 2019 EPS Diluted$43.64$43.64N/M vs Q3 2019 Gross Profit$367,300,000+19.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flowderived$135,664,000+36.0% Free Cash Flowderived$115,686,000+68.5% Margins · derivedGross margin56.7%+2.0 pt vs Q3 2019
Operating margin16.9%+6.7 pt vs Q3 2019
Net margin203.1%+249.3 pt vs Q3 2019
ended Sep 30, 2020 · filed Oct 30, 2020 · 30 d after period end